Watch for Some Gout Patients to Switch From Uloric to Allopurinol

September 2018

Please see the February 2019 FDA advisory concerning the increased risk of death with Uloric (Febuxostat).

You may get fewer Rxs for febuxostat (Uloric) for gout...due to concerns it increases risk of death.

Patients with gout are already at elevated cardiovascular risk.

Now febuxostat is under fire due to recent studies suggesting it may cause more cardiovascular deaths than allopurinol in some patients.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Vaccines Stay Sharp to Prevent Errors With Vaccines
Recalls Navigate Through the Valsartan Recall
Lice Sort Through Head Lice Treatments
Cannabinoids Be Ready for Questions About Cannabidiol (CBD)
Eczema Know How Eucrisa and Dupixent Stack Up Against Other Eczema Meds
Diabetes & Endocrinology Keep Meds for Male-Pattern Hair Growth in Women Straight
Antibiotics Expect Less Use of Quinolones Based on the Latest Warnings
Psoriasis Think of Siliq as Similar to Cosentyx or Taltz for Plaque Psoriasis
Cardiology Repatha's Heart Benefits Are Driving Labelling Changes
Gout Watch for Some Gout Patients to Switch From Uloric to Allopurinol